Study of Leuprorelin in Premenopausal Breast Cancer Patients
Author Information
Author(s): M. Dowsett, A. Mehta, J. Mansi, I.E. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
Does the lower dose of leuprorelin (3.75 mg) provide similar effectiveness as the higher dose (7.5 mg) in suppressing estrogen levels in premenopausal breast cancer patients?
Conclusion
The study found that both doses of leuprorelin effectively suppressed estrogen levels without significant differences in their effectiveness.
Supporting Evidence
- Both doses of leuprorelin suppressed estrogen levels to within the postmenopausal range.
- Two patients responded positively to the lower dose, indicating its potential effectiveness.
- Hot flushes were the main side effect experienced by the majority of patients.
Takeaway
Doctors tested two doses of a medicine called leuprorelin to see if a smaller dose works just as well as a bigger dose for women with breast cancer. They found that both doses worked well.
Methodology
Twelve premenopausal patients were randomized to receive either 3.75 mg or 7.5 mg of leuprorelin every 4 weeks, and hormone levels were measured before and during treatment.
Potential Biases
Potential selection bias due to the small number of participants.
Limitations
The small sample size limits the generalizability of the results.
Participant Demographics
All participants were premenopausal women with advanced breast cancer, either estrogen receptor positive or unknown.
Statistical Information
P-Value
0.002
Confidence Interval
15-72%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website